February 2010
Sanaria Receives Multi-Year U.S. NIH Phase II Small Business Innovation Research grant to develop a genetically attenuated whole parasite malaria vaccine; Press Release
February 2010
Medicine in Need (MEND) receives $3 million grant from the Bill and Melinda Gates Foundation to apply advanced formulation technologies to the stabilization of new malaria vaccine candidates, including Sanaria's PfSPZ vaccine; Press Release
January 2010
Dr. David Dolberg, Sanaria's Director of Intellectual Property, is recognized for his contributions to paradigm changing research in cancer; Information
January 2010
Sanaria featured in Volume 6, Issue 1, the January cover, of the Human Vaccines Journal
September 2009
Sanaria honored to be ranked 22nd among all Maryland businesses in The Gazette of Politics and Business Exceptional 53 Business Award; Announcement
September 2009
Sanaria receives multi-year U.S. NIH phase II Small Business Innovation Research grant to enhance efficiency and scale-up of its malaria vaccine manufacturing process; Press Release
July 2009
Sanaria and Sanaria's CEO, Dr. Stephen L. Hoffman, featured in U.S. News and World Report article, Why a Man Let 2,000 Malaria-Infected Mosquitoes Bite Him; usnews.com
June 2009
Sanaria featured in Associated Press article, Pulling malaria from mosquitoes to fight disease
April 2009
Sanaria and PATH-MVI announce that Phase 1 trial of Sanaria's whole-parasite malaria vaccine called PfSPZ Vaccine to begin; FDA approval for testing in humans watershed moment for unique malaria vaccine approach; Press Release
April 2009
Sanaria wins Vaccine Industry Excellence Award for Best Early-Stage Vaccine Biotech at the World Vaccine Congress Washington. Other awardees include GlaxoSmithKline Biologicals and PATH Malaria Vaccine Initiative for Best Vaccine Partnership/Alliance, GlaxoSmithKline Biologicals for Best Vaccine R&D Pipeline, and Merck for Best Prophylactic Vaccine; ViE; Press Release